Silver Book Fact

Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.

Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al. Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications. Value in Health. 2001; 4(2): 158. https://www.valueinhealthjournal.com/article/S1098-3015(11)71392-4/abstract

Reference

Title
Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications
Publication
Value in Health
Publication Date
2001
Authors
Provenzano, George, Sandeep Duttagupta, Thomas McRae, et al
Volume & Issue
Volume 4, Issue 2
Pages
158
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $25 billion in 2050–from the…  
  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicare costs for people with the disease would be…  
  • Americans Age 65 and Older with Alzheimer’s Disease, 2010–2050